The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2020 | CMWP & EBMT report: allogeneic HCT outcomes in myeloma patients on renal replacement
Meral Beksac, MD, Ankara University, Ankara, Turkey, discusses a Chronic Malignancies Working Party (CMWP) and European Society for Blood and Marrow Transplantation (EBMT) report that investigated allogeneic hematopoietic cell transplantation (HCT) outcomes in myeloma patients on renal replacement. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
